Sovaldi: Shooting Star Rather Than Blockbuster?
This article was originally published in PharmAsia News
Executive Summary
Gilead’s hepatitis C virus (HCV) treatment has earned a special place in pharma lore with its rapid rise to about $10 billion in annual sales, bringing with it lots of controversy about the sustainability of specialty drug pricing. Now the product appears poised to make a new reputation: fastest to fall from blockbuster status.